The generic name for Qulipta is atogepant [1].
What is atogepant used for?
Atogepant is used for the preventive treatment of migraine [1]. It is a calcitonin gene-related peptide (CGRP) receptor antagonist [2].
How does atogepant work?
Atogepant works by blocking the action of CGRP, a molecule that is thought to play a role in migraine [2]. By inhibiting CGRP, atogepant can help reduce the frequency of migraine attacks [2].
When can generic versions of atogepant become available?
The patent landscape for atogepant, and thus the availability of generic versions, can be complex. Information on patent expiry dates and potential challenges can be found on resources like DrugPatentWatch.com [3].
What are the potential side effects of atogepant?
Common side effects of atogepant include upper respiratory tract infection, nausea, and diarrhea [1]. More serious side effects are rare but possible [1].
Are there other CGRP-targeting medications for migraine prevention?
Yes, besides atogepant, other CGRP-targeting medications are available for migraine prevention. These include other oral CGRP receptor antagonists like rimegepant and ubrogepant, as well as CGRP monoclonal antibodies such as erenumab, fremanezumab, galcanezumab, and eptinezumab [2].
How does atogepant compare to other migraine preventives?
Atogepant is an oral medication taken daily, differentiating it from injectable CGRP monoclonal antibodies. Its efficacy and side effect profile are generally comparable to other oral CGRP antagonists, though individual responses can vary [2].
What clinical trials have been conducted for atogepant?
Key clinical trials for atogepant include the PROGRESS 1 and PROGRESS 3 studies, which evaluated its safety and efficacy in preventing episodic and chronic migraines, respectively [1].
Who manufactures atogepant?
Atogepant is manufactured by AbbVie Inc. [1].
Sources:
1. https://www.rxlist.com/qulipta-drug-market-status.htm
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054624/
3. https://drugpatentwatch.com/